Gedeon Richter Media Richter publishes Q3 results
Richter publishes Q3 results
06/11/2025
Temporarily slowing dynamics in Q3
  • Pharma revenues grew by 7% to HUF 669bn in Q1-Q3 2025. Innovative businesses (WHC and CNS/Vraylar®) sustained strong momentum, however, the affordable pillar faced multiple headwinds in Q3. Ex-FX revenue growth was 5.4%.
  • Net profit was at HUF 163bn in Q1-Q3 2025, 7% lower YoY, as higher operating profits were offset by FX losses. Free cash-flow generation was outstanding and increased by 22% YoY to HUF 200bn in Q1-Q3 2025.
  • Full-year guidance was revised: Ex-FX revenues are expected to be close to EUR 2.3bn in 2025, while ex-FX Clean EBIT is to increase by 8-10%.

 

Budapest, 6 November 2025 - Gedeon Richter Plc. (“Richter”) announced today its Q1-Q3 2025 financial results.

Pharma revenues declined by 1% YoY to HUF 211.2bn in Q3 2025, bringing Q1-Q3 2025 revenues to HUF 669bn (+7% YoY). Excluding currency changes (ex-FX), revenue growth was 5.4% in Q1-Q3 2025, somewhat lagging the annual plan. 

  • CNS revenues increased by 10% in Q1-Q3 2025 YoY on the back of continued strong demand growth for Vraylar®. Reagila® sales were slightly weaker YoY despite continued double-digit growth seen in Richter’s own network, as revenues from some partnered territories decreased due to overstock, timing of deliveries and price decreases.
  • Women’s Healthcare sales growth kept its strong momentum in Q3, growing double-digit, keeping the ytd increase at 11% (ex-FX). The leading products (Drovelis®, Ryeqo®, Lenzetto®, Evra®) were the key growth drivers, while the traditional portfolio also delivered some growth. Western European markets were the strongest contributors growing nearly 20% both in Q3 and Q1-Q3 YoY.
  • BIO revenues further slowed in Q3. While teriparatide sales continued to increase YoY, CDMO revenues declined on lower revenue booking on some contracts and some production delays at the new line.
  • GenMed revenues declined materially in Q3, hit by the combination of supply problems/stockouts affecting a key product, wholesaler destocking across several CEU/EEU markets and a high base. As a result, FX-adjusted revenues were down by 3% in Q1-Q3 2025.

Gross profit (pharma) grew by 6% to HUF 463bn, while gross margin was marginally lower (-0.3ppt) at 69.2% in Q1-Q3 2025.

Clean EBIT (pharma) declined by 7% YoY to HUF 66bn in Q3 2025, almost fully driven by the weaker GenMed contribution, bringing Q1-Q3 Clean EBIT to HUF 213bn, up by 7%. CER (ex-FX) Clean EBIT increased by 6% YoY in Q1-Q3 2025.

Reported EBIT stood at HUF 204.5bn in Q1-Q3 2025, rising 7.5% YoY.

Net profit (attributable to the owners of the parent) was HUF 163bn in Q1-Q3 2025, declining by 7% from last year, as net financials were negative (HUF 9.5bn net expenses) in 2025 due to large FX losses.

Free cash flow (before M&A) increased by 22% to HUF 200bn in Q1-Q3, as higher EBIT, lower capex and a much smaller increase in net working capital than a year ago led to outstanding cash generation. Apart from the payment of the regular annual dividend (HUF 93bn, paid in Q2), only some minor transactions required the use of cash to date, implying that a considerable part of the FCF added to the net cash position.

 

Gábor Orbán, CEO commented the results:

“Our innovative businesses in Women’s Health and Neuropsychiatry continued to deliver strong momentum, achieving double-digit revenue growth and our cash generation is very strong overall. In contrast, GenMed’s topline faced several headwinds in Q3, including supply chain disruptions that caused stockouts for a key product, wholesaler destocking across multiple markets, regulatory changes, and a high prior-year base. CDMO revenues also fell short of the expected run rate. However, given steady growth in in-market sales, we anticipate most of these challenges will ease or disappear in the coming months. Accordingly, we have adjusted our full-year guidance and now expect CER revenues to be close to EUR 2.3 billion, with CER Clean EBIT projected to grow by 8–10% in 2025. The relative strength of our bottomline reflects disciplined cost control and the benefits of our long-standing efficiency initiatives.“

 

About Gedeon Richter Plc.

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.7bn and sales of EUR 2.2bn in 2024, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com

 

For further information:

Investors: Róbert Réthy, CFA                                                                      +36 20 342 2555

Media:      Zsuzsa Beke                                                                               +36 20 916 4507